Furthermore, combining CALLY with molecular and genomic markers such as MSI, KRAS, and BRAF mutations, as well as circulating tumor DNA (ctDNA), could generate more comprehensive predictive models that align with the principles of precision oncology. The gene discussed is KRAS; the disease is neoplasm.